The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized, single center trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056931

Enrollment

Unknown

Registered

2022-02-23

Start date

2020-01-01

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Therapy for Helicobacter pylori eradication

Interventions

A group:Antofloxacin-based bismuth quadruple therapy

B group:Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy

Eligibility

Sex/Gender

All

Age

19 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-70 years; 2. Patients who were diagnosed with H. pylori infection through 13/14C-urea breath test (13/14C-UBT) or histological evaluation; 3. Never received H. pylori eradication therapy.

Exclusion criteria

Exclusion criteria: 1. Those patients who were allergic to proton pump inhibitor, bismuth, penicillin,and quinolone drugs; 2. Those patients who suffered from gastrectomy before; 3 Patients with malignant tumors, severe heart, liver, or renal dysfunction; 4. Patients with pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
The rate of H. pylori eradication;The frequency of adverse events;	—

Secondary

Measure	Time frame
The severity of adverse events;	—

Countries

China

Contacts

Public ContactXiao-Jian He

Department of Digestive Diseases, The 900th Hospital of the PLA Joint Logistic Support Force

627858017@qq.com+86 17758929990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026